Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $3.0400 (-6.75%) ($3.0200 - $3.0400) on Fri. Dec. 31, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.75% (three month average) | RSI | 18 | Latest Price | $3.0400(-6.75%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -5% a day on average for past five trading days. | Weekly Trend | HTBX declines -10.3% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(51%) ARKG(50%) ARKK(50%) EEM(50%) ONLN(50%) | Factors Impacting HTBX price | HTBX will decline at least -1.375% in a week (0% probabilities). VXX(-40%) VIXM(-40%) UUP(-16%) TLT(-13%) GLD(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.375% (StdDev 2.75%) | Hourly BBV | -2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-13.14(-532.24%) | Resistance Level | $3.81 | 5 Day Moving Average | $3.26(-6.75%) | 10 Day Moving Average | $3.58(-15.08%) | 20 Day Moving Average | $3.81(-20.21%) | To recent high | -49.5% | To recent low | 0% | Market Cap | $334m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |